BioCentury | Jul 17, 2018
Distillery Therapeutics

Infectious disease

...linked to a conjugate of an HIV tat protein (HIV tat)-derived peptide and a mouse defensin...
BioCentury | Jan 12, 2018
Clinical News

Innovation's Brilacidin-OM meets in Phase II for oral mucocitis

...to discuss next steps with FDA. Brilacidin-OM is an oral rinse formulation of a synthetic defensin...
...Mass. Product: Brilacidin-OM Business: Other Molecular target: NA Description: Oral rinse formulation of a synthetic defensin...
BioCentury | Oct 31, 2017
Distillery Therapeutics

Transplant

...GvHD pathology. Next steps include testing RSPO1 in other dysbiosis-associated diseases. TARGET/MARKER/PATHWAY: R-Spondin 1 (RSPO1); defensin...
...online Oct. 24, 2017 doi:10.1084/jem.20170418 CONTACT: Takanori Teshima, Hokkaido University, Sapporo, Japan email: teshima@med.hokudai.ac.jp Michael Leviten Hokkaido University Defensin...
BioCentury | Oct 27, 2017
Preclinical News

RSPO1 restores gut biome in GvHD

...alpha defensins in feces compared with vehicle. Quantitative PCR of Paneth cells showed increased alpha defensin...
...damage, and prevented intestinal stem cell damage compared with vehicle. RSPO1 also restored fecal alpha defensin...
...alpha defensin dosing could modify gut microbiota, the researchers generated a highly bactericidal mouse alpha defensin...
BioCentury | May 24, 2017
Clinical News

Cellceutix completes enrollment in Phase II for ulcerative proctitis

...change in MMDAI score, quality of life (QOL), safety and pharmacokinetics. Brilacidin is a synthetic defensin...
...enema. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin Business: Autoimmune Molecular target: NA Description: Synthetic defensin...
BioCentury | Jun 27, 2016
Clinical News

Brilacidin: Phase II started

...patients. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin Business: Autoimmune Molecular target: NA Description: Synthetic defensin...
BioCentury | Jan 28, 2016
Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 5 (RANTES; CCL5); defensin α 1 (DEFA1; HNP-1)

...models of cardiovascular disease and inflammation. TARGET/MARKER/PATHWAY: Chemokine CC motif ligand 5 (RANTES; CCL5 ); defensin...
BioCentury | Jun 25, 2015
Distillery Techniques

Techniques: SNPs within defensin α 1 (DEFA1; HNP-1)/defensin β 1 (DEFB1) gene cluster and other loci as risk markers for IgA nephropathy

Biomarkers DEFA1 DEFB1 defensin HNP-1 Sun Yat-sen University BC Staff...
BioCentury | Jun 15, 2015
Clinical News

Brilacidin-OM: Phase II started

...Mass. Product: Brilacidin-OM Business: Other Molecular target: NA Description: Oral rinse formulation of a synthetic defensin...
BioCentury | Feb 23, 2015
Emerging Company Profile

Eyeing new antibiotics

...SpearHead antimicrobial is a dimeric cationic peptide that was synthesized based on the human beta defensin...
Items per page:
1 - 10 of 76